Anti-PD-1 monoclonal antibody (specialist)
Cemiplimab
Brand names: Libtayo
Adult dose
Dose: 350mg IV q3w
Route: IV
Frequency: q3w
Clinical pearls
- NICE TA592 / TA770: cutaneous SCC, basal cell carcinoma; TA770 / TA noting NSCLC
- ESMO Immuno-oncology toxicity guidelines
- Specialist dermato-oncology / oncology
Contraindications
- Active autoimmune disease (relative)
- Solid organ transplant (relative)
- Hypersensitivity
Side effects
- Immune-related adverse events: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatitis, myocarditis
- Infusion reactions
- Fatigue
Interactions
- Systemic corticosteroids (avoid prophylactic; use to manage irAEs)
Monitoring
- TFTs
- Cortisol
- LFTs
- Renal
- Glucose
- irAE symptoms
Reference: BNF; NICE TA592; NICE TA770; ESMO; SmPC; https://bnf.nice.org.uk/drugs/cemiplimab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina